

Emcure Pharmaceuticals Achieves Strong Q1FY26 Performance with 16% Revenue Growth and 41% Profit After Tax Growth

- Revenue from operations at Rs. 2,101Cr, up 15.7% YoY
- EBITDA margins at 19.2% with EBITDA up 20.1% YoY
- PAT at Rs. 215 Cr, up 41% YoY
- Domestic business sales at Rs. 995 Cr, up 9.4% YoY
- International business sales at Rs. 1,106 Cr, up 22.1% YoY

Pune, Aug 7, 2025: Emcure Pharmaceuticals (BSE: 544210, NSE: EMCURE) today announced its consolidated financial results for the quarter ended June 30th, 2025.

The quarter saw robust performance from both Domestic and International businesses. Emcure's International business grew 22% with all businesses performing. Rest of the World business continued the healthy momentum growing 42%. Company's Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%.

Domestic business grew 9.4% led by strong performance in all out key therapies and aided by new initiatives in Derma and OTC. During the quarter, the company further strengthened its domestic business through expansion of its strategic partnership with Sanofi. Going forward, Emcure will be marketing and distributing Sanofi's Oral Anti-diabetic portfolio in addition to the cardiovascular portfolio.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, "We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets through in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins. "

Revenue break-up:

Rs. Cr	1Q26	1Q25	YOY%	4Q25	QOQ%
Revenue from operations	2,101	1,815	15.7%	2,116	-0.7%
Domestic	995	909	9.4%	929	7.1%
International	1,106	906	22.1%	1,187	-6.9%
EM	360	254	41.9%	481	-25.1%
EU	403	358	12.8%	396	1.9%
CA	342	294	16.4%	310	10.1%

Contd.

Performance Summary (Consolidated)

Rs. Cr	1Q26	1Q25	YOY%	4Q25	QOQ%
Revenue from operations	2,101	1,815	15.72%	2,116	-0.74%
Material Cost	802	683	17.41%	892	-10.10%
Gross Profit	1,299	1,132	14.71%	1,224	6.08%
<i>Gross Profit Margins</i>	<i>61.8%</i>	<i>62.4%</i>		<i>57.8%</i>	
Employee Costs	393	350	12.29%	373	5.39%
Other expenses	501	445	12.54%	461	8.75%
EBITDA	404	336	20.09%	390	3.58%
<i>EBITDA Margins</i>	<i>19.23%</i>	<i>18.53%</i>		<i>18.43%</i>	
Other Income	4	23		4	
Depreciation and Amortisation	99	94		97	
Finance Costs inc. Forex	14	59		26	
Exceptional Items	4	0		10	
Profit Before Tax (PBT)	291	207	40.19%	261	11.57%
Tax	76	55		63	
Profit After Tax (PAT)	215	153	40.76%	197	8.90%
<i>PAT Margins</i>	<i>10.2%</i>	<i>8.4%</i>		<i>9.3%</i>	

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Contact:

Media

corpcomm@emcure.com

Investor Relations

investor.relations@emcure.com

Details of the Earnings Call:

- **Date:** Thursday, Aug 07, 2025
- **Time:** 3:30 p.m. – 4:30 p.m. (IST)
- **Dial-In Numbers:**
 - Universal Access: [+91 22 6280 1220](tel:+912262801220) / [+91 22 7115 8122](tel:+912271158122)
 - USA: 1 866 746 2133
 - UK: 0 808 101 1573
 - Singapore: 800 101 2045
 - Hong Kong: 800 964 448